Phase 2 study of nilotinib as third-line therapy for patients with gastrointestinal stromal tumor

Cancer

Volumn 117, Issue 20, 2011, Pages 4633-4641

  Sawaki, Akira ^a   Nishida, Toshirou ^b   Doi, Toshihiko ^c   Yamada, Yasuhide ^d   Komatsu, Yoshito ^e   Kanda, Tatsuo ^f   Kakeji, Yoshihiro ^g   Onozawa, Yusuke ^h   Yamasaki, Makoto ^b   Ohtsu, Atsushi ^c  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^d NATIONAL CANCER CENTER HOSPITAL   (Japan)

^e HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

^f NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^g KYUSHU UNIVERSITY   (Japan)

^h SHIZUOKA CANCER CENTER   (Japan)

Author keywords

gastrointestinal; kinases; nilotinib; protein tyrosine; stromal; tumors

Indexed keywords

IMATINIB; NILOTINIB; SUNITINIB;

ABDOMINAL PAIN; ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; AREA UNDER THE CURVE; ARTICLE; CANCER CONTROL; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CONSTIPATION; DECREASED APPETITE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXON; FATIGUE; FEMALE; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; HUMAN; HUMAN TISSUE; HYPERBILIRUBINEMIA; JAPAN; LYMPHOCYTE; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; ONCOGENE C KIT; OPEN STUDY; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PLATELET DERIVED GROWTH FACTOR RECEPTOR ALPHA GENE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QT PROLONGATION; SIDE EFFECT; SUDDEN DEATH; TIME TO MAXIMUM PLASMA CONCENTRATION; TORSADE DES POINTES;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; INDOLES; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MUTATION; NEOPLASM GRADING; NEOPLASM STAGING; PIPERAZINES; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; PYRROLES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; SALVAGE THERAPY; TIME FACTORS; TREATMENT OUTCOME;

EID: 79959985933     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26120     Document Type: Article

References (29)

1. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998; 279: 577-580. (Pubitemid 28067289)
2. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003; 21: 4342-4349. (Pubitemid 46621810)
3. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003; 299: 708-710. (Pubitemid 36159485)
4. Blay JY, Le Cesne A, Ray-Coquard I, et al. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol. 2007; 25: 1107-1113. (Pubitemid 46596763)
5. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002; 347: 472-480. (Pubitemid 34879334)
6. Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet. 2004; 364: 1127-1134. (Pubitemid 39296599)
7. Zalcberg JR, Verweij J, Casali PG, et al. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer. 2005; 41: 1751-1757. (Pubitemid 41132637)
8. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006; 368: 1329-1338. (Pubitemid 44528723)
9. Dileo P, Bauer S, Van Den Abbeele A, et al. Results with AMN107, a novel kinase inhibitor, in gastrointestinal stromal tumor (GIST): preclinical rationale and early results in a patient (Pt) with imatinib (IM)-resistant GIST [abstract]. Presented at ASCO Gastrointestinal Cancers Symposium; January 28-30, 2006; San Francisco, CA; Abstract 53.
10. Agaram NP, Besmer P, Wong GC, et al. Pathologic and molecular heterogeneity in imatinib-stable or imatinib-responsive gastrointestinal stromal tumors. Clin Cancer Res. 2007; 13: 170-181. (Pubitemid 46121866)
11. Agaram NP, Laquaglia MP, Ustun B, et al. Molecular characterization of pediatric gastrointestinal stromal tumors. Clin Cancer Res. 2008; 14: 3204-3215.
12. Crossman LC, Druker BJ, Deininger MW, et al. hOCT 1 and resistance to imatinib. Blood. 2005; 106: 1133-1134.
13. Prenen H, Guetens G, de Boeck G, et al. Cellular uptake of the tyrosine kinase inhibitors imatinib and AMN107 in gastrointestinal stromal tumor cell lines. Pharmacology. 2006; 77: 11-16.
14. Thomas J, Wang L, Clark RE, et al. Active transport of imatinib into and out of cells: implications for drug resistance. Blood. 2004; 104: 3739-3745. (Pubitemid 39564452)
15. White DL, Saunders VA, Dang P, et al. OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood. 2006; 108: 697-704. (Pubitemid 44061372)
16. Demetri GD, Casali PG, Blay JY, et al. A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors. Clin Cancer Res. 2009; 15: 5910-5916.
17. Montemurro M, Schoffski P, Reichardt P, et al. Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib. Eur J Cancer. 2009; 45: 2293-2297.
18. Demetri GD, Huang X, Garrett CR, et al. Novel statistical analysis of long-term survival to account for crossover in a phase III trial of sunitinib (SU) vs. placebo (PL) in advanced GIST after imatinib (IM) failure [abstract]. J Clin Oncol. 2008; 26. Abstract 10524.
19. Reichardt P, Blay J, Gelderblom H, et al. Phase III trial of nilotinib in patients with advanced gastrointestinal stromal tumor (GIST): first results from ENEST g3 [abstract]. J Clin Oncol. 2010; 28: 10017.
20. Antonescu CR, Besmer P, Guo T, et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res. 2005; 11: 4182-4190. (Pubitemid 40791584)
21. Gramza AW, Corless CL, Heinrich MC,. Resistance to tyrosine kinase inhibitors in gastrointestinal stromal tumors. Clin Cancer Res. 2009; 15: 7510-7518.
22. Chen LL, Trent JC, Wu EF, et al. A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res. 2004; 64: 5913-5919. (Pubitemid 39129383)
23. Heinrich MC, Maki RG, Corless CL, et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol. 2008; 26: 5352-5359.
24. Manley PW, Stiefl N, Cowan-Jacob SW, et al. Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib. Bioorg Med Chem. 2010; 18: 6977-6986.
25. Guo T, Agaram NP, Wong GC, et al. Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor. Clin Cancer Res. 2007; 13: 4874-4881. (Pubitemid 47294795)
26. Guyton AC, Hall JE,. Textbook of Medical Physiology. 10th ed. Philadelphia, PA: Saunders; 2000.
27. Joensuu H, Trent JC, Reichardt P,. Practical management of tyrosine kinase inhibitor-associated side effects in GIST. Cancer Treat Rev. 2011; 37: 75-88.
28. le Coutre P, Ottmann OG, Giles F, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood. 2008; 111: 1834-1839. (Pubitemid 351451490)
29. Tojo A, Usuki K, Urabe A, et al. A phase I/II study of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL. Int J Hematol. 2009; 89: 679-688.